Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (MRNS) announced plans to release its third-quarter financial results on November 8, 2022, before U.S. market opening. A conference call will follow at 8:30 a.m. ET, accessible via the Investor page on Marinus' website. Marinus focuses on developing innovative therapeutics for seizure disorders, with its product ZTALMY® approved for treating seizures associated with CDKL5 deficiency disorder. The company is also exploring ganaxolone's potential in other seizure disorders through ongoing Phase 3 trials.

Positive

• ZTALMY® is FDA-approved for treating CDKL5 deficiency disorder, enhancing revenue potential.
• Phase 3 trials for ganaxolone in tuberous sclerosis complex and refractory status epilepticus could lead to further product approvals.

Negative

• None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022. The Company will host a conference call at 8:30 a.m. Eastern Time on November 8, 2022.

Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_ᴀ receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005036/en/

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When will Marinus Pharmaceuticals release its Q3 2022 financial results?

Marinus Pharmaceuticals plans to release its Q3 2022 financial results on November 8, 2022.

What time is Marinus Pharmaceuticals' conference call scheduled for?

The conference call for Marinus Pharmaceuticals is scheduled for 8:30 a.m. ET on November 8, 2022.

What product does Marinus Pharmaceuticals have approved?

Marinus Pharmaceuticals' product ZTALMY® (ganaxolone) is approved for treating seizures associated with CDKL5 deficiency disorder.

What other conditions are being studied by Marinus Pharmaceuticals?

Marinus is studying ganaxolone for other seizure disorders, including in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus.

Where can I access the Marinus Pharmaceuticals conference call?

The conference call can be accessed via the Investor page on Marinus' website.